Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535263 | 0.82 | KIF11 (0.42) | KIF11GABRA1GABRB3GABRG2ADORA2A | |
| SCHEMBL992639 | 0.80 | GABRA1 (0.47) | KIF11GABRA1GABRB3GABRG2ADORA2A | |
| SCHEMBL993942 | 0.80 | KIF11 (0.45) | KIF11GABRA1GABRB3GABRG2ADORA2A | |
| SCHEMBL18969110 | 0.80 | KIF11 (0.41) | KIF11GABRA1GABRB3GABRG2GABRB2 | |
| Hydrochloric Acid SCHEMBL993872 | 0.78 | KIF11 (0.44) | KIF11GABRA1GABRB3GABRG2ADORA2A | |
| SCHEMBL17600537 | 0.78 | KIF11 (0.41) | KIF11GABRA1GABRB3GABRG2ADORA2A | |
| SCHEMBL18969775 | 0.77 | KIF11 (0.40) | KIF11GABRA1GABRB3GABRG2GABRB2 | |
| SCHEMBL15892710 | 0.77 | ESR1 (0.44) | KIF11GABRA1GABRB3GABRG2ADORA2A | |
| SCHEMBL4659933 | 0.77 | KIF11 (0.45) | KIF11GABRA1GABRB3GABRG2GABRB2 | |
| SCHEMBL20336329 | 0.76 | KIF11 (0.61) | KIF11GABRA1GABRB3GABRG2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225336-A1 | MET BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2021018857-A1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2021-02-04 | — | — | WO | disclosed |
| US-8933065-B2 | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140342989-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-20 | — | — | US | disclosed |
| EP-2262764-B1 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | UNIV NORTH CAROLINA (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8829033-B2 | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2509939-A2 | NOVEL N-BENZYLAMIDE SUBSTITUED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACY-LAMIDO) PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | The University of North Carolina At Chapel Hill (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120232015-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-09-13 | — | — | US | disclosed |
| WO-2011037833-A2 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-03-31 | — | — | WO | disclosed |
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2011-01-27 | — | — | US | disclosed |
| EP-2262764-A2 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | The University of North Carolina At Chapel Hill (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009145816-A2 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, GBA1 | KIF11 2086/4885GABRA1 69/4885GABRB3 116/4885 |
| US-20140342989-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, APEH | KIF11 1903/4885GABRA1 67/4885GABRB3 95/4885 |
| US-20120232015-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, APEH | KIF11 1880/4885GABRA1 67/4885GABRB3 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.